Evaluation of platelet‐rich plasma plus basic fibroblast growth factor combined with minoxidil in the treatment of androgenetic alopecia: A randomized controlled trial

    TLDR Using platelet-rich plasma, basic fibroblast growth factor, and minoxidil together significantly increases hair count and growth rate in people with hair loss.
    A randomized controlled trial involving 75 patients evaluated the effectiveness of platelet-rich plasma plus basic fibroblast growth factor (PRPF) combined with minoxidil in treating androgenetic alopecia. The study found that all treatments led to a significant increase in hair count and density, with the combination of PRPF and minoxidil showing the highest improvement. The terminal hair count increased from 99.24 ± 24.47 to 125.88 ± 24.15 and hair growth rate increased from 0.70 ± 0.01 mm/day to 0.83 ± 0.12 mm/day. The telogen hair ratio, representing the percentage of hairs in the resting phase, decreased significantly from 33.03 ± 4.15% to 21.50 ± 3.42%. However, there were no significant changes in vellus hair count, ratio, and mean hair thickness over time. The study concluded that PRPF treatment is efficient and safe, and combination therapy is important for treating androgenetic alopecia.
    View this study on onlinelibrary.wiley.com →

    Cited in this study

    Related